NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials - Company enhances patient recruitment by employing patient data for deeper visibility into test patterns and patient groups - ClinicalTrials.gov / LabCorp.com / Covance.com / Frost.com
Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials

 

NewswireToday - /newswire/ - Santa Clara, CA, United States, 2020/12/23 - Company enhances patient recruitment by employing patient data for deeper visibility into test patterns and patient groups - ClinicalTrials.gov / LabCorp.com / Covance.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes LabCorp’s drug development business, Covance, with the 2020 Global CRO Company of the Year Award. The company has built technology-enabled solutions to assist clients with drug development across all therapeutic areas. Its robust supply chain and logistical capabilities help scale up and efficiently manage material handling to provide clients with customized solutions, particularly for biologics drug development.

Spearheading a decentralized trial model to facilitate seamless clinical trials, LabCorp Drug Development integrates digital technologies, remote monitoring, and telemedicine services into its powerful proprietary clinical trial platform. It offers several patient-centric solutions, such as direct-to-patient services and digital solutions to strengthen patient retention, safety, patient engagement, and patient experience to support ongoing and new research programs. By capturing robust, real-time patient data, the company guides clinical decisions, reduces costs and errors, and accelerates the drug’s time-to-market.

“LabCorp Drug Development has developed highly coordinated COVID-19 Response Teams to expedite clients’ COVID-19 drug and vaccine development initiatives. By connecting pharmaceutical clients to the right personnel, it allows them to move between development stages rapidly,” said Supriya Lala Kundu, best practices research analyst at Frost & Sullivan. “By accessing Patient Direct, a company database of consented, pre-screened patients meeting specific inclusion/exclusion criteria, LabCorp Drug Development can conduct targeted patient recruitment. Furthermore, LabCorp Drug Development draws on its deep expertise in antiviral drugs and vaccines, as well as partners with biopharmaceutical companies to develop treatment and vaccines for COVID-19 through improved detection methods.”

At the beginning of June, LabCorp Drug Development launched COVID-19clinicaltrialconnect.com/, a website designed to help people find information on how to participate in United States-based COVID-19 studies. The site notifies potential participants of studies in their area and other studies included in clinicaltrials.gov. LabCorp Drug Development also supports its customers with a proactive crisis management plan to support their existing patient programs and prevent uninterrupted patient access. Additionally, a cross-functional team with business continuity expertise evaluates risk, develops mitigation strategies, and establishes action plans to minimize country-, project- and site-specific challenges for high-risk project delivery.

“LabCorp Drug Development views its real-world data, modeling/analytics, and patient insights as essential to improving patient recruitment and retention. It uniquely combines one of the world’s largest sources of de-identified lab results and patient intelligence data with investigator performance data to provide insights that increase efficiencies in clinical drug development,” noted Kundu.

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

About LabCorp

LabCorp (labcorp.com), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Lindsey Whitaker - Frost.com 
210-477-8457 lindsey.whitaker[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study
South Carolina-based IMCS Awarded Major NIH Research Grant
Preventive Healthcare Measures to Combat Obesity and Lifestyle Diseases Steer Demand for Nutritional Lipids Globally Finds Frost & Sullivan
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa
Global Biosimilars Market Poised to Grow At Chart-topping Levels with a CAGR of 17.3%, Reaching .2 Billion by 2026 Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  SlideUpLift





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)